DYN
NASDAQDyne Therapeutics Inc.
News · 26 weeks158-24%
2026-03-012026-08-23
Mix7790d
- SEC Filings34(44%)
- Insider26(34%)
- Other10(13%)
- Offering4(5%)
- Analyst2(3%)
- Leadership1(1%)
Latest news
25 items- PRDyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WALTHAM, Mass., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 11 newly hired employees. The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 161,300 shares of Dyne’s common stock at a per share exercise price equal to the closing price of Dyne’s common stoc
- INSIDERDirector Rhodes Jason P sold $65,184,894 worth of shares (2,586,928 units at $25.20) as part of a pre-agreed trading plan (SEC Form 4)4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- INSIDERChief Commercial Officer Friedl-Naderer Johanna sold $5,939 worth of shares (226 units at $26.28) as part of a pre-agreed trading plan, decreasing direct ownership by 0.15% to 153,982 units (SEC Form 4) to satisfy withholding tax4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- INSIDERChief Medical Officer Kerr Douglas sold $40,892 worth of shares (1,556 units at $26.28) as part of a pre-agreed trading plan, decreasing direct ownership by 0.92% to 167,599 units (SEC Form 4) to satisfy withholding tax4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- INSIDERCEO & President Cox John sold $131,032 worth of shares (4,986 units at $26.28) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 363,165 units (SEC Form 4) to satisfy withholding tax4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- INSIDERChief Financial Officer Lucera Erick sold $47,225 worth of shares (1,797 units at $26.28) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 119,766 units (SEC Form 4) to satisfy withholding obligation4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Dyne Therapeutics Inc.SCHEDULE 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Dyne Therapeutics Inc.SCHEDULE 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Dyne Therapeutics Inc.SCHEDULE 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECDyne Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Dyne Therapeutics, Inc. (0001818794) (Filer)
- PRDyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights- Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 - - Completed enrollment of 71 participants in registrational expansion cohort of Phase 1/2 ACHIEVE trial of z-basivarsen in DM1; topline data planned for Q1 2027 - - Investigational New Drug (IND) Application cleared by FDA for DYNE-302 in FSHD - - Expected cash runway into Q2 2028 - WALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today rep
- INSIDERDirector Kersten Dirk sold $6,670,769 worth of shares (261,460 units at $25.51) as part of a pre-agreed trading plan (SEC Form 4)4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- SECSEC Form 10-Q filed by Dyne Therapeutics Inc.10-Q - Dyne Therapeutics, Inc. (0001818794) (Filer)
- PRDyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)- Company’s third program to enter clinical development leveraging FORCE platform with the goal of delivering functional improvement in rare neuromuscular disease - WALTHAM, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its IND application to initiate a Phase 1 clinical trial for DYNE-302 in facioscapulohumeral muscular dystrophy (FSHD). DYNE-302 leverages the same FORCE™ platform as Dyne’s first two clinical programs, zelec
- PRDyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WALTHAM, Mass., July 24, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 12 newly hired employees. The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 358,600 shares of Dyne’s common stock at a per share exercise price equal to the closing price of Dyne’s common stoc
- PRDyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesWALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the closing of its previously announced upsized underwritten public offering of 21,045,000 shares of its common stock at a public offering price of $20.50 per share, which includes 2,745,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The gross proceeds to Dyne from the offering were approximately $431.4 million, before deducting underwriting discounts and comm
- ANALYSTCantor Fitzgerald initiated coverage on Dyne TherapeuticsCantor Fitzgerald initiated coverage of Dyne Therapeutics with a rating of Overweight
- SECSEC Form 424B5 filed by Dyne Therapeutics Inc.424B5 - Dyne Therapeutics, Inc. (0001818794) (Filer)
DYN FAQ
7 questionsWhat does Dyne Therapeutics Inc. do?
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.Where does DYN stock trade?
Dyne Therapeutics Inc. (DYN) is listed on NASDAQ.What sector and industry is DYN in?
Dyne Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Dyne Therapeutics Inc. go public?
Dyne Therapeutics Inc. (DYN) completed its IPO in 2020.What are analysts saying about DYN?
Dyne Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight on 2026-07-23. Recent price targets range from $1300.00 to $4000.00.What companies are similar to DYN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare DYN side-by-side with any of them on Quantisnow.How can I track DYN on Quantisnow?
Quantisnow aggregates Dyne Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DYN to receive live email and push alerts on every new disclosure.